NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Active Not RecruitingPhase 2

Sponsor: Incyte Corporation

Conditions: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer

Interventions: Ruxolitinib, Capecitabine, Regorafenib

Countries: United States, Poland

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
* Currently tolerating treatment in the parent protocol.
* Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
* Have at least stable disease, as determined by the investigator.
* Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

Exclusion Criteria:

* Has been permanently discontinued from study treatment in the parent study for any reason.
* Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Locations (9)

Santa Monica, California, United States
Louisville, Kentucky, United States
Clifton Park, New York, United States
Nashville, Tennessee, United States
Houston, Texas, United States
The Woodlands, Texas, United States
Krakow, Poland
Lublin, Poland
Warsaw, Poland